This research from Osaka University, published in European Heart Journal in January 2023, presents a significant breakthrough in treating triglyceride deposit cardiomyovasculopathy (TGCV), a specific type of coronary artery disease. Led by Ken-ichi Hirano, researchers discovered that tricaprin, a commercially available dietary supplement, dramatically reversed atherosclerotic lesions and relieved symptoms in patients with TGCV, a condition they had identified 15 years earlier. TGCV differs from traditional atherosclerosis as it involves triglyceride deposits in blood vessels due to defective cellular breakdown, making it resistant to standard treatments. The study focused on two patients with diabetes and refractory chest pain who showed remarkable improvement after taking tricaprin, which promotes lipid breakdown in heart muscle cells. This represents the first documented case of atherosclerosis regression through increased triglyceride lipolysis within cells, offering hope for patients who don't respond to conventional coronary artery disease treatments.
Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar
Comparison of the two high-intensity statins: both lower LDL-C by 50% or more, rosuvastatin is more potent per milligram, but in the randomized LODESTAR trial 3-year clinical outcomes did not differ significantly. The goal is reaching the appropriate LDL target on maximally tolerated therapy.



